ABSTRACT
INTRODUCTION
High-resolution cytogenetic testing is recommended in pregnancies with ultrasound anomalies and stillbirth 1 , but only a few centers offer microarray analysis to all pregnant women with an indication for invasive testing [2] [3] [4] . Because of the invasive character of chorionic villus sampling and amniocentesis, genomic microarray data are available only for a limited number of pregnancies, so it is difficult to assess the background risk for structural aberrations in uneventful pregnancies. As, so far, no association has been identified between the prevalence of submicroscopic findings and maternal age 5 , we assumed that pregnancies without ultrasound anomalies or aberrant family history could be used as representative of the general population when studying submicroscopic pathogenic chromosomal aberrations.
Non-invasive trisomy testing in cell-free DNA (cfDNA) is becoming more popular in low-risk populations, and technical advances already allow non-invasive testing with a resolution similar to that of karyotyping 6 ; thus, we anticipate that high-resolution non-invasive cfDNA testing, with resolution comparable with that of genomic microarray, will become available to the general population in the near future. This may raise the question whether such high-resolution testing is justifiable in low-risk pregnancies. Moreover, the additional need for confirmatory studies and extensive post-test genetic counseling in cases with positive screening results will be mandatory and this may, in theory, exceed the current capacity of prenatal centers. To assess whether high-resolution testing may be of additional value in all pregnancies, we investigated how often a submicroscopic finding could be expected in the general population. To answer this question, a systematic review of the prevalence of pathogenic genomic submicroscopic imbalances in pregnancies without any increased risk for structural chromosomal aberrations was performed.
METHODS

Search strategy
Because microarray testing has so far been performed only on samples obtained using invasive procedures, we analyzed pregnancies without an increased risk for structural chromosomal aberrations, namely pregnant women tested invasively because of advanced maternal age (AMA), who are at increased risk for aneuploidy as a result of non-disjunction, or pregnancies tested because of parental anxiety (ANX), without any medical indication for cytogenetic testing.
EMBASE, PubMed, Web of Science and the Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched in order to identify all relevant articles on the prevalence of pathogenic submicroscopic copy number variants (CNVs) in fetuses referred for prenatal invasive testing because of AMA or ANX. The search strategy was developed in consultation with an experienced research librarian on 3 June 2016. A string of the terms 'array' and 'prenatal', and their synonyms, was used to identify all relevant publications (full search details are given in Appendix S1). The search was restricted to publications in the English language and to human populations involving more than five subjects (Figure 1 ). Conference abstracts were excluded from the search. Duplicates were removed automatically by the Biomedical Information Specialist of Erasmus MC 7, 8 . Five reviewers (M.I.S., M.J., M.F.C.M.K., A.T.J.I.G. and D.V.O.) screened independently the titles and abstracts of all retrieved articles for relevance. Published manuscripts that potentially contained results of pregnancies with AMA or ANX indications were selected for critical appraisal of the full text. Only cohorts including more than five fetuses without ultrasound anomalies were included. Studies that did not use a genomic microarray technique in the prenatal setting, reviews, case reports and studies in which prenatal genomic array was performed only because of ultrasound anomalies were excluded from full-text analysis. Details of the exclusion criteria are given in Figure 1 .
Thirty-six publications were selected for full-text analysis and underwent a second trial of selection according to strict inclusion criteria, in order to obtain a homogeneous pooled population from which the prevalence of pathogenic submicroscopic findings could be calculated. The criteria were: (1) papers that described fetuses with a known normal karyotype or described their cohort in such a manner that fetuses with large genomic aberrations of > 10 Mb could be excluded; (2) publications that described the composition of their cohort in such a way that the total number of fetuses referred because of AMA and/or ANX could be retrieved; and (3) publications that showed the pathogenic CNVs in detail and related to the referral reason or at least gave the number of pathogenic CNVs per group of fetuses with AMA/ANX.
Finally, 19 publications were selected for detailed review. The selected articles were subjected to a critical appraisal designed by the authors and met the criteria. This appraisal included features of quality-assessment tools and used sample size, cohort selection, the description quality of the cohort (specification of the testing indication) and CNV classification as the parameters for assessment. Quality assessment of the selected publications was performed according to the Newcastle-Ottawa Scale (NOS), modified for the purpose of the study. Specifically, comparability was dependent on whether the cohort size was > 300, as preliminary results showed that smaller cohorts may not be representative, and the outcomes were dependent on the molecular description of the submicroscopic findings.
Data extraction
The total number of 'karyotypically normal' fetuses was extracted from individual papers (i.e. the total number of fetuses referred for invasive testing because of AMA/ANX was extracted from the cohorts and aberrations larger than 10 Mb were excluded from both total numbers and results). Microarray results in each publication were evaluated based on the array nomenclature provided by the authors, and early-onset syndromic disorders, susceptibility CNVs and late-onset disorders were identified amongst all pathogenic CNVs.
To enhance reliable estimation of the prevalence of pathogenic CNVs in the presence of low event rates, studies with a minimum sample size of n > 300 were selected. This cut-off for the cohort size was chosen after preliminary analysis showed that the background risk for an early-onset disorder associated with a submicroscopic CNV, estimated based on all 19 papers, was 1 in 294. Furthermore, the onset/penetrance of the submicroscopic Studies included in meta-analysis (n = 10)
Figure 1
Flowchart of search strategy and selection of studies on prevalence of pathogenic submicroscopic copy number variants in fetuses referred for prenatal invasive testing because of advanced maternal age or parental anxiety, for inclusion in systematic review and meta-analysis.
findings was studied in a subset of papers (n = 8) that presented aberrant cases with all necessary details. The prevalence of pathogenic CNVs and its 95% CI was calculated using a random-effects model 9 in Comprehensive Meta-Analysis software version 2 (Biostat Inc., Englewood, NJ, USA) that employs standard continuity corrections for zero-events cells.
Additionally, based on current knowledge (case reports in the literature) and the clinical experience of the clinicians in our center, the possibility of detecting the particular chromosomal aberration on a routine fetal anomaly scan (FAS) in the second trimester was assessed. The CNVs were classified into three groups: (1) aberrations associated with phenotypes that are either not detectable or are unlikely to be detectable on routine FAS (e.g. imbalances associated with dysmorphic facial features and intellectual disability); (2) aberrations for which detection on ultrasound is uncertain and dependent on the variable phenotype or penetrance (e.g. not all carriers of 22q11 microduplications present heart anomalies that could be detected on ultrasound); and (3) aberrations associated with phenotypes likely to be detectable on routine FAS (associated with major structural fetal anomalies, present in all affected fetuses).
Susceptibility CNVs were often classified as uncertain as some of the affected fetuses may show ultrasound anomalies. Subtelomeric aberrations that are typically found in cohorts of patients with intellectual disability without other structural congenital anomalies (clearly detectable on ultrasound) and late-onset disorders were classified as unlikely to be detectable on ultrasound. All cases were discussed individually and, if required, literature search was performed to assess this probability.
RESULTS
Search results
The electronic search yielded 4252 articles, of which 36 2,4,10-43 were reviewed in full text. Several potentially relevant papers were excluded because they did not include patients with isolated AMA or ANX 14, 41 , the total number of AMA/ANX patients tested with microarray could not be retrieved 27, 35, 36, 40 , the referral groups were not described clearly (it was unclear whether the patients presented isolated AMA) 30 or non-homogeneous categories were used (e.g. included maternal anxiety because of advanced maternal age, family history of genetic disorder or previous child with anomalies in one category) 17 .
Papers describing overlapping cohorts that were included in later publications of the same group were excluded, for example the cohort of Fiorentino and colleagues 2011 16 is included in Fiorentino et al. 2013 2 and that of Bi and colleagues 10 is described in Van Den Veyver et al. 37 .
Based on the inclusion and exclusion criteria, the five reviewers agreed on the relevance and sufficient quality of 19 articles (Table S1 ). Even though the aberrations were not specified clearly in some papers, if the total number of tested and total number of abnormal cases per referral reason could be retrieved, these were included for preliminary determination of the prevalence 11, 33, 39 . Some authors did not specify the chromosomal breakpoints 4, 18, 32 or genome build that was used 2, 20, 43 , but the papers were included in the review. We observed a wide variety of array platforms used in the reviewed studies with respect to array technology (e.g. single nucleotide polymorphism (SNP) arrays, oligonucleotide microarrays and bacterial artificial chromosomes (BACs) array) and their resolution (many were semi-targeted with high resolution in regions of interest and low-resolution backbone). Most papers published utilized semi-targeted BAC microarrays or an oligonucleotide array and only a few used SNP-based arrays 24, 38, 39 . All 19 publications included in the systematic review were scored according to the designed NOS quality assessment, which allowed further selection of studies for the meta-analysis. Results of the quality assessment of the included publications are shown in Table S2 .
Frequency of submicroscopic findings
Details of the 10 studies that included cohorts of > 300 fetuses and were used for determining the frequency of submicroscopic pathogenic findings are shown in Table 1 , including array platforms, cohort size and number of clinically significant submicroscopic findings. The estimated proportions (event rates), together with 95% CI, of abnormal cases in these papers, including the pooled estimate based on the random-effects model, are shown in Figure 2 . The pooled estimate indicated that 0.84% (95% CI, 0.55-1.30%) of fetuses that had invasive testing because of AMA/ANX carried a pathogenic clinically significant submicroscopic aberration. It is noteworthy that there is substantial heterogeneity among the proportions of abnormal cases in the selected studies (Figure 2) .
The onset/penetrance of submicroscopic findings could be studied in 10 314 fetuses reported in eight papers that included cohorts of > 300 and presented aberrant cases with all necessary details to allow interpretation of these findings (Table 2) 2, 4, 19, 20, 25, 32, 38, 43 . All aberrations and their classifications are shown in Table S3 . Pooled estimates resulting from meta-analysis of the data indicated that an early-onset syndromic disorder was detected in 0.37% (95% CI, 0.27-0.52%) of cases, a susceptibility CNV was found in 0.30% (95% CI, 0.14-0.67%) and late-onset diseases were reported in 0.11% (95% CI, 0.05-0.21%). All evaluated CNVs associated with early-onset syndromic disorders were either unlikely to be detectable on routine second-trimester FAS (47%) or the detection was uncertain, being dependent on (variable) phenotype or penetrance (53%). Therefore, detection of these disorders by routine ultrasound was assessed as generally unlikely.
Most CNVs are located in the interstitial part of the chromosome. Only two unbalanced translocations were found. Uniparental disomy (n = 1) and low-level mosaicism (n = 3) were reported in only one paper, in which a SNP array platform was used 38 . There was no statistically significant difference in the prevalence of syndromic findings between pregnancies tested because of AMA and those referred for ANX (Table 1) , which may suggest that submicroscopic findings are not age-related (29/7597 (0.38%) in AMA vs 13/2970 (0.43%) in ANX, χ 2 (1) = 0.17, P = 0.681). As there is no consensus about reporting susceptibility CNVs in prenatal settings, we have further analyzed the syndromic early-onset disorders, as we believe that these are in the scope of prenatal testing (0.37%; 95% CI, 0.27-0.52%) (35/10 314; 0.34%). These involved various genetic diseases -known microdeletion syndromes, such as 15q11q13 deletion syndrome (causing either Prader-Willi or Angelman syndrome) or Williams-Beuren syndrome, and other known genetic disorders, such as Charcot-Marie-Tooth neuropathy or Duchenne Muscular Dystrophy (DMD) -but most were deletions of various chromosomal regions causing loss and disruption of many genes and leading to intellectual disability, developmental delay, dysmorphic features and variable structural anomalies (Table S3) .
Estimation of background risk for chromosomal aberrations
The preliminary estimation of the risk for early-onset disorder associated with a submicroscopic aberration based on all 19 relevant studies was 1 in 294. Therefore, the final estimation was based on papers presenting cohorts of > 300 that presented details over the pathogenic CNVs. According to meta-analysis of the relevant data, the risk for an early-onset disorder associated with a submicroscopic chromosomal aberration was calculated to be 1 in 270, based on 0.37% (95% CI, 0.27-0.52%) cases in which aberrations were specified ( Table 2 ). Next to this background risk, every woman has a risk for aneuploidy because of her age and a risk for other (structural) chromosomal aberrations that, similarly to submicroscopic aberrations, seems to not be age-related 5 . The individual risks for a chromosomal aberration were recalculated based on the data currently available. The risk for Down syndrome, the risk for microscopically visible chromosomal aberrations (after Hook and colleagues 5 ) and the combined risks for both microscopic and submicroscopic aberrations per age category are shown in Table 3 . As there is no report that submicroscopic aberrations are maternal-age related, which is also supported by this review, an identical risk of Table 1 Relevant publications (n = 10) with cohorts of > 300 cases reviewed in current study and used for determination of frequency of submicroscopic pathogenic findings in fetuses that underwent invasive testing because of advanced maternal age (AMA) or parental anxiety (ANX) 20 1 Only first author is given for each study. *Total number of cases with a specific indication concerns fetuses without microscopically visible aberrations (> 10 Mb); this means that these are either karyotypically normal fetuses or aberrations larger than 10 Mb and detectable on karyotype were excluded. †Unspecified CNVs; therefore, CNVs from this paper are not included in Table 2 (unknown size and nature of the clinically significant array finding). aCGH, array comparative genomic hybridization; BAC, bacterial artificial chromosome; BCM, The Baylor College of Medicine; CGH, comparative genomic hybridization; CNV, copy number variant; sCNV, susceptibility CNV for neurodevelopmental disorder; SNP; single nucleotide polymorphism. Only first author is given for each study. AMA, advanced maternal age; ANX, parental anxiety; CNV, copy number variant.
1 in 270 was used for all age categories. When the risk for submicroscopic aberrations is added to the individual risk for microscopic chromosomal aberrations, all pregnant women have a risk of higher than 1 in 180 for a relevant chromosomal aberration, and pregnant women under 36 years of age have a higher risk for submicroscopic pathogenic aberrations than for Down syndrome.
DISCUSSION
It is challenging to assess the background risk for submicroscopic pathogenic findings in the general pregnant population as microarray testing is restricted mainly to high-risk pregnancies. The background frequency of submicroscopic pathogenic findings was Study Armengol (2012) 43 Lee (2012) 20 Wapner (2012) 39 Shaffer (2012) 4 Breman (2012) 11 Fiorentino (2013) 2 Scott (2013) 32 Konialis (2015) 19 Papoulidis (2015) 25 Van Opstal (2015) 38 Study statistics previously assessed based on unexpected diagnoses in fetuses that were prenatally tested with microarray. The background population risk was estimated to be as high as 0.3-0.5% based on single studies 4, 44 . The purpose of the present study was to estimate, based on a systematic review of the literature, the frequency of pathogenic submicroscopic chromosomal aberrations in fetuses that are not at increased risk for unbalanced structural chromosomal aberrations, in order to determine whether high-resolution cytogenetic investigations are of additional value in low-risk pregnancies.
Based on the systematic review and meta-analysis of the data, a risk of 0.86% (1 in 116) (Table 1) for a submicroscopic pathogenic aberration can be expected in uneventful pregnancies. In 0.34% of karyotypically normal fetuses, the submicroscopic CNV involves an early-onset disorder. The majority are associated with developmental delay/intellectual disability and are not likely to be detectable on ultrasound. A significant number of these syndromes are actually more severe than Down syndrome. There was no statistically significant difference between the incidence of submicroscopic chromosomal aberrations associated with syndromic disorder in patients tested because of AMA and those tested because of ANX, which supports the hypothesis that the risk for submicroscopic imbalances is not related to the age of the pregnant woman. Nevertheless, older pregnant women tend to have partners of a similar age and there is no consensus in the literature as to whether the risk for CNVs might be related to paternal age 45, 46 . Besides the risk for submicroscopic aberrations, every pregnant woman has her own risk for chromosomal aberrations based on her age 5, 47, 48 . When the risk for submicroscopic aberrations was added to the individual risk for microscopic chromosomal aberration, all pregnant women had a risk of higher than 1 in 180 for a relevant chromosomal aberration. Comparing this risk with the iatrogenic miscarriage risk by invasive testing 49 this could be considered as a valid indication for invasive cytogenetic prenatal diagnosis. Pregnant women under 36 years of age have a higher risk for submicroscopic pathogenic aberrations than for Down syndrome; therefore, a screening test for more than the common aneuploidies seems to be most appropriate for low-risk pregnancies.
Nowadays, patients may face a choice between invasive tests that can be followed by microarray analysis and a routine non-invasive test that is generally thought to be safer, but with a resolution that is often dramatically lower than even standard karyotyping and with a chance for both false-negative and false-positive results, mainly as a result of placental mosaicism. Only some laboratories offer genome-wide extended intrachromosomal analysis [50] [51] [52] [53] . We strongly advocate giving patients up-to-date information on the risks for all chromosomal aberrations as presented in this paper, as well as the recent risk figures for miscarriage due to invasive procedures 49, 54 so that they can make an informed choice.
As early detection of fetal unbalanced chromosomal aberrations is desired, non-invasive whole-genome profiling in the first trimester of pregnancy would allow detection of genetic disorders before the abnormal phenotype can be detected and preferably before fetal movements can be felt by the pregnant woman. According to some authors, non-invasive prenatal testing (NIPT) already allows screening with a resolution similar to karyotyping and many efforts have been made to introduce screening also for submicroscopic aberrations 6, 52, 53, [55] [56] [57] [58] [59] [60] . If a robust, non-invasive, high-resolution test is implemented and widely chosen, one could expect to detect approximately 30-40 additional cases with pathogenic CNVs of < 10 Mb, which may involve an early-onset syndromic disorder, per every 10 000 pregnant women. These would require additional genetic post-test counseling and a confirmatory invasive test. This situation is unlikely to cause capacity problems in local genetic centers and laboratories, especially because the implementation of NIPT has been shown to lead to a decreased number of invasive procedures in countries in which NIPT is now available.
Limitations of this study are the fact that most of the patients were selected for invasive procedures and the diversity of the array designs used. The majority of studies used oligonucleotide arrays that are unable to detect uniparental disomy (UPD). Moreover, most studies focussed on submicroscopic CNVs; however, it is known that apart from UPD, other chromosomal aberrations, such as low mosaic aberrations and cryptic translocations, will be missed by karyotyping and therefore these can also be considered to be submicroscopic aberrations. The differences in resolution, design and probe coverage between microarrays mean that not all types of microarray can detect all submicroscopic CNVs. Therefore, the prevalence shown in this review is very likely to have been underestimated.
In conclusion, based on the available literature, highresolution cytogenetic testing (invasive or non-invasive) is of additional value in pregnancies without an increased risk for structural chromosomal aberrations. Especially in young women, the risk for submicroscopic pathogenic aberrations seems to be higher than that for Down syndrome. The risk for submicroscopic pathogenic aberrations, as assessed in this paper, needs to be added to the well-known risks for common trisomies and microscopically visible aberrations. Pretest counseling should be updated with new data on risks both for all chromosomal aberrations and miscarriage as a result of invasive procedures in experienced centers so that pregnant women and their partners can make informed choices. As currently routine, high-resolution genome-wide diagnostic testing is possible only on fetal tissue obtained using an invasive procedure and because invasive testing in all pregnancies does not seem to be feasible in clinical settings, a reliable, non-invasive whole-genome profiling test to screen for both microscopic and submicroscopic aberrations is highly desirable.
ACKNOWLEDGMENT
We would like to thank Gerdien B. de Jonge (Biomedical Information Specialist of Erasmus MC) for her assistance in performing the systematic search and removing the duplicate papers during the review process.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Appendix S1 Systematic literature search details Table S1 Nineteen relevant publications reviewed in current study and used for preliminary determination of frequency of submicroscopic pathogenic findings in fetuses tested due to advanced maternal age (AMA) or parental anxiety (ANX) 
